Legend Capital invests in Series A funding round of BioMap, a biological computing platform Jul 30, 2021 16:58 HKT/SGT Read More
エーザイとバイオジェン、Lecanemab(BAN2401)の臨床効果についてアルツハイマー病協会国際会議2021(AAIC2021)のLate Breakingとして発表 Jul 30, 2021 10:00 JST Read More
エーザイとバイオジェン、アルツハイマー病の初めてのリアルワールド観察臨床第IV相試験となるADUHELM ICARE AD-USの試験デザインをアルツハイマー病協会国際会議2021において発表 Jul 30, 2021 10:00 JST Read More
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401) Jul 30, 2021 09:07 HKT/SGT Read More
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021 Jul 30, 2021 08:24 HKT/SGT Read More
Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment Jul 29, 2021 16:34 HKT/SGT Read More
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021 Jul 27, 2021 08:00 HKT/SGT Read More
Singapore cord blood bank Cryoviva establishes footprint in the UAE Jul 27, 2021 08:00 HKT/SGT Read More
エーザイ、「レンビマ(R)」(レンバチニブ)と「キイトルーダ(R)」(ペムブロリズマブ)の併用療法について進行性子宮内膜がんに係る承認を米国FDAより取得 Jul 26, 2021 09:00 JST Read More
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma Jul 23, 2021 08:17 HKT/SGT Read More
Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic Jul 22, 2021 19:26 HKT/SGT Read More
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021 Jul 21, 2021 09:34 HKT/SGT Read More